Difference between revisions of "Conflict of interest"
(Created page with " {{TOC limit|limit=3}} ==Introduction== With the September 2018 expose in the New York Times on Jose Baselga, a leader in the field of breast oncology and medical oncology as...") |
|||
| Line 7: | Line 7: | ||
*9/8/2018, NYT: [https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals] | *9/8/2018, NYT: [https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals] | ||
*9/13/2018, NYT: [https://www.nytimes.com/2018/09/13/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties] | *9/13/2018, NYT: [https://www.nytimes.com/2018/09/13/health/jose-baselga-cancer-memorial-sloan-kettering.html Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties] | ||
| + | *9/14/2018, NYT: [https://www.nytimes.com/2018/09/14/opinion/jose-baselga-research-disclosure-bias.html Transparency Hasn’t Stopped Drug Companies From Corrupting Medical Research] | ||
==What we are doing== | ==What we are doing== | ||
Revision as of 18:44, 14 September 2018
Introduction
With the September 2018 expose in the New York Times on Jose Baselga, a leader in the field of breast oncology and medical oncology as a whole, public awareness of financial conflicts of interest in hematology/oncology is on the rise. Financial and other conflicts of interest are not new to biomedicine but can certainly diminish trust in the profession. We plan to develop this page as an archive of lay media and peer-reviewed literature covering the topic; it will be expanded over time.
Jose Baselga controversy
- 9/8/2018, NYT: Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals
- 9/13/2018, NYT: Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
- 9/14/2018, NYT: Transparency Hasn’t Stopped Drug Companies From Corrupting Medical Research
What we are doing
HemOnc.org was founded with the goal of creating a freely available, comprehensive, centralized repository of chemotherapy drug and treatment regimens. From the beginning, our philosophy has been to remain ad-free, revenue-neutral, and an international community resource without paywalls or registration requirements. In the interests of transparency, we will be adding financial conflict of interest disclosures to our Editorial Board page. If you have other thoughts about how we can maximize transparency, please contact us at [email protected].